Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Somatic Activating ESR1 Mutation in an Aggressive Prolactinoma.
Paes T, Buelvas Mebarak J, Magnotto JC, Stamatiades GA, Kuang Y, Paweletz C, Laws ER, Grosek N, Carroll RS, Jeselsohn R, Mohan DR, Lerario AM, Truong MT, Bi WL, Reardon DA, Meredith DM, Kaiser UB, Abreu AP. Paes T, et al. Among authors: paweletz c. J Clin Endocrinol Metab. 2024 Sep 6:dgae615. doi: 10.1210/clinem/dgae615. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 39238355
Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
Khalsa JK, Cha J, Utro F, Naeem A, Murali I, Kuang Y, Vasquez K, Li L, Tyekucheva S, Fernandes SM, Veronese L, Guieze R, Sasi BK, Wang Z, Machado JH, Bai H, Alasfour M, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Paweletz CP, Leshchiner I, Parida L, Getz G, Brown JR. Khalsa JK, et al. Among authors: paweletz cp. Blood. 2023 Aug 3;142(5):421-433. doi: 10.1182/blood.2022016600. Blood. 2023. PMID: 37146250 Free PMC article.
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Odintsov I, Makarem M, Nishino M, Bachert SE, Zhang T, LoPiccolo J, Paweletz CP, Gokhale PC, Ivanova E, Saldanha A, Rudin CM, Lockwood WW, Ladanyi M, Somwar R, Jänne PA, Sholl LM. Odintsov I, et al. Among authors: paweletz cp. J Thorac Oncol. 2024 May;19(5):732-748. doi: 10.1016/j.jtho.2023.12.019. Epub 2023 Dec 26. J Thorac Oncol. 2024. PMID: 38154514
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
Hanna GJ, Villa A, Nandi SP, Shi R, ONeill A, Liu M, Quinn CT, Treister NS, Sroussi HY, Vacharotayangul P, Goguen LA, Annino DJ Jr, Rettig EM, Jo VY, Wong KS, Lizotte P, Paweletz CP, Uppaluri R, Haddad RI, Cohen EEW, Alexandrov LB, William WN Jr, Lippman SM, Woo SB. Hanna GJ, et al. JAMA Oncol. 2024 Jan 1;10(1):32-41. doi: 10.1001/jamaoncol.2023.4853. JAMA Oncol. 2024. PMID: 37971722 Free PMC article.
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
Hanna GJ, Dharanesswaran H, Giobbie-Hurder A, Harran JJ, Liao Z, Pai L, Tchekmedyian V, Ruiz ES, Waldman AH, Schmults CD, Riella LV, Lizotte P, Paweletz CP, Chandraker AK, Murakami N, Silk AW. Hanna GJ, et al. Among authors: paweletz cp. J Clin Oncol. 2024 Mar 20;42(9):1021-1030. doi: 10.1200/JCO.23.01498. Epub 2024 Jan 22. J Clin Oncol. 2024. PMID: 38252908 Free PMC article. Clinical Trial.
CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer.
Tarannum M, Dinh K, Vergara J, Birch G, Abdulhamid YZ, Kaplan IE, Ay O, Maia A, Beaver O, Sheffer M, Shapiro R, Ali AK, Dong H, Ham JD, Bobilev E, James S, Cameron AB, Nguyen QD, Ganapathy S, Chayawatto C, Koreth J, Paweletz CP, Gokhale PC, Barbie DA, Matulonis UA, Soiffer RJ, Ritz J, Porter RL, Chen J, Romee R. Tarannum M, et al. Among authors: paweletz cp. Sci Adv. 2024 Jul 12;10(28):eadn0881. doi: 10.1126/sciadv.adn0881. Epub 2024 Jul 12. Sci Adv. 2024. PMID: 38996027 Free PMC article.
Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
Wang Y, Buck A, Piel B, Zerefa L, Murugan N, Coherd CD, Miklosi AG, Johal H, Bastos RN, Huang K, Ficial M, Laimon YN, Signoretti S, Zhong Z, Hoang SM, Kastrunes GM, Grimaud M, Fayed A, Yuan HC, Nguyen QD, Thai T, Ivanova EV, Paweletz CP, Wu MR, Choueiri TK, Wee JO, Freeman GJ, Barbie DA, Marasco WA. Wang Y, et al. Among authors: paweletz cp. Mol Cancer. 2024 Mar 16;23(1):56. doi: 10.1186/s12943-024-01952-w. Mol Cancer. 2024. PMID: 38491381 Free PMC article.
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Oliveira G, Egloff AM, Afeyan AB, Wolff JO, Zeng Z, Chernock RD, Zhou L, Messier C, Lizotte P, Pfaff KL, Stromhaug K, Penter L, Haddad RI, Hanna GJ, Schoenfeld JD, Goguen LA, Annino DJ, Jo V, Oppelt P, Pipkorn P, Jackson R, Puram SV, Paniello RC, Rich JT, Webb J, Zevallos JP, Mansour M, Fu J, Dunn GP, Rodig SJ, Ley J, Morris LGT, Dunn L, Paweletz CP, Kallogjeri D, Piccirillo JF, Adkins DR, Wu CJ, Uppaluri R. Oliveira G, et al. Among authors: paweletz cp. Sci Immunol. 2023 Sep 8;8(87):eadf4968. doi: 10.1126/sciimmunol.adf4968. Epub 2023 Sep 8. Sci Immunol. 2023. PMID: 37683037 Free PMC article.
141 results